President Donald Trump’s drug pricing initiative, TrumpRx, is growing by incorporating 600 new generic medications and teaming up with billionaire investor Mark Cuban from “Shark Tank.”
The website, which started earlier this year, aims to help consumers secure “prescriptions at the lowest possible cost,” Trump mentioned during a press conference at the White House alongside Cuba’s president.
TrumpRx.gov has been enhanced to offer users a user-friendly way to find generic equivalents of brand-name drugs with just a click. Additionally, it provides maps showing nearby medicine prices and delivery options.
“Americans have been paying significantly higher drug prices than people in other countries for decades,” Trump stated. “Now we are seeing the lowest prices possible globally.”
While TrumpRx itself doesn’t sell medications, it guides users to platforms that do, including the Mark Cuban Cost Plus Drug Company, which ships medicines directly to customers.
Cuban expressed, “It’s clear that everyone—Republicans, independents, and Democrats—wants more affordable drugs. I believe we can unite for something meaningful.” He’s notably been a critic of the complex drug pricing system.
Interestingly, Cuban supported Kamala Harris in the 2024 presidential race and has criticized Trump in the past. He mentioned that Trump could repeat his earlier mistakes. However, at the press conference, Trump seemed to have moved on from their past disagreements.
He remarked, “Cuban made a significant error, yes, but he runs a solid company and will engage in substantial business here.”
As a demonstration of the website’s capabilities, they showcased the diabetes drug Glucophage, priced at around $20, but the generic version, metformin, was only $8.42.
The administration has emphasized its partnerships with pharmaceutical companies to reduce prices within government programs and directly supply drugs to consumers, aiming to enhance healthcare affordability.
TrumpRx is also promoting substantial discounts on many brand-name medications through special “most-favored-nation” pricing agreements negotiated with drug manufacturers.
Initially, the site featured a range of brand-name drugs, including those for diabetes, weight loss, fertility treatments, and various cancers. Some medications now have discounts of over 80% compared to their original prices.
For example, Wegovy, a weight loss drug, starts at $149, down from $1,349.02, representing an astounding 89% discount. Ozempic, another diabetes medication, has a starting price of $199 compared to $1,027.51.
Similarly, the fertility drug Cetrotide is sold at $22.50, a major reduction from $316.12, and the diabetes medication Gentaduet is listed for $55, down from $525.08.
Other significant discounts feature Mayzent for multiple sclerosis at “from $42” instead of $623; Farxiga for $35 instead of $377.82; and Amjevita, a Humira biosimilar, priced at $299 rather than $1,484.16.
These discounts are part of a White House initiative encouraging pharmaceutical companies to align U.S. prices with those of other countries.
The expansion of TrumpRx comes as more manufacturers sign contracts with the government.
For instance, Boehringer Ingelheim has partnered with the platform to offer diabetes medications like GentaDuet and GentaDuet XR, as well as the COPD inhaler Strivardi Respimat.
Novartis has committed to providing drugs such as Mayzent, the leukemia treatment Lydapt, and Tabrecta for lung cancer.
Moreover, Amgen has incorporated medications like the migraine treatment Aimovig and cholesterol-lowering drug Repatha into the system.
GSK has also added an antiviral drug, Relenza, and multiple inhaled medications including Inclux, Alnuity, and Anoro Ellipta.
Cuban’s involvement in some drug pricing initiatives displays a curious political alignment over the issue, as he has often identified as an independent but supported a range of Democratic candidates in the past.
His recent efforts aim to enhance the affordability of generic drugs through reforms targeting price disclosures and eliminating intermediaries in the pharmaceutical supply chain.
Cuban noted that middlemen, often referred to as pharmacy benefit managers, tend to push for higher prices to boost their own profits.
